A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
Status:
Terminated
Trial end date:
2011-09-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by
IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor
malignancies and lymphomas.